Founded in April 2019, RNACure BioPharma is an innovative drug company focused on mRNA technology innovation and product development. We have built a full-chain mRNA drug technology platform spanning target discovery, sequence design, delivery systems, manufacturing processes, quality control, supply chain, and industrialization. The core team comprises leading scientists from Harvard, Yale, the Karolinska Institute, Peking University, PUMC, and other renowned institutions, with more than a decade of mRNA research experience. We are committed to breakthroughs in foundational mRNA technologies, building an integrated R&D-to-manufacturing platform, advancing an end-to-end mRNA industry ecosystem, accelerating clinical translation of mRNA medical products, and driving development across infectious disease vaccines, cancer vaccines, protein replacement therapy, gene-editing therapy, and veterinary vaccines, aiming to become a global leader in mRNA drug R&D.